Inspira Technologies Granted Patent in Japan for the INSPIRA™ ART System's Convertible Dual Lumen Cannula Device and Method of Use - Inspira Technologies Oxy (NASDAQ:IINN)

Core Viewpoint - Inspira Technologies has secured a significant patent for its Convertible Dual Lumen Cannula device in Japan, enhancing its market position in the medical device sector and supporting future commercialization efforts [1][2]. Group 1: Patent and Market Position - The Japan Patent Office granted Patent No. 7777598, providing Inspira exclusive commercial rights for the Dual Lumen Cannula technology in Japan until 2041 [2]. - This patent complements an existing U.S. Patent granted in 2023, creating a protective barrier across two major healthcare markets [2]. - The patented technology allows a single-lumen cannula to convert into a dual-lumen cannula intravascularly, which may reduce infection risks and procedural complications compared to traditional solutions [3]. Group 2: Product and Strategic Implications - The Convertible Dual Lumen Cannula is designed to be a high-value disposable product, potentially enhancing patient safety and procedural efficiency while being more affordable than traditional dual-lumen cannulas [4]. - The company is positioned to benefit from both its respiratory support platforms and future disposable revenue streams due to the proprietary protection in the U.S. and Japan [4]. - Inspira Technologies is advancing its product offerings, including the INSPIRA™ ART100 system for cardiopulmonary bypass and the next-generation INSPIRA ART500 system, which aims to deliver oxygenation while patients remain awake [5].